Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.

Molecular cancer therapeutics - 1 Aug 2017

Nelson-Taylor Sarah K, Le Anh T, Yoo Minjae, Schubert Laura, Mishall Katie M, Doak Andrea, Varella-Garcia Marileila, Tan Aik-Choon, Doebele Robert C

Abstract excerpt

Oncogenic rearrangements in RET are present in 1%-2% of lung adenocarcinoma patients. Ponatinib is a multi-kinase inhibitor with low-nanomolar potency against the RET kinase domain. Here, we demonstrate that ponatinib exhibits potent antiproliferative activity in RET fusion-positive LC-2/ad lung adenocarcinoma cells and inhibits phosphorylation of the RET fusion protein and signaling through ERK1/2 and AKT. Using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to MAP Kinase Signaling System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Axl Receptor Tyrosine Kinase

Share to Gene Rearrangement

Share to GTP Phosphohydrolases

Share to Oncogenes

Share to Proto-Oncogene Proteins c-ret

Share to Pyridazines

Source

Open in PubMed Open full text

Identifiers

PMID: 28500237
DOI: 10.1158/1535-7163.MCT-17-0008
PMCID: PMC5544556

Genes

RET
NRAS
AXL
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.PMID 28500237Read ↗

Targeting RET alterations in non-small cell lung cancer.Semantic proximity Read ↗

Treatment of non–small cell lung cancer with RET rearrangementsSemantic proximity Read ↗

RET fusions observed in lung and colorectal cancers are sensitive to ponatinibSemantic proximity Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.Semantic proximity Read ↗

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathwaySemantic proximity Read ↗

Therapeutic strategies in RET gene rearranged non-small cell lung cancerSemantic proximity Read ↗

Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cellsSemantic proximity Read ↗

Current management of RET rearranged non-small cell lung cancerSemantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.